Skip to Content

Brodalumab Pregnancy and Breastfeeding Warnings

Brodalumab is also known as: Siliq

Brodalumab Pregnancy Warnings

In animal studies, no adverse developmental effects were observed in offspring after subcutaneous administration of this drug during organogenesis through parturition at doses up to 26 times the maximum recommended human dose (MRHD). There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

This drug should be used during pregnancy only if the benefit outweighs the risk. US FDA pregnancy category: Not assigned. Risk Summary: There are no data on the use of this drug in pregnant women. Human IgG antibodies are known to cross the placental barrier; therefore, the drug may be transmitted from the mother to the developing fetus. Comments: -Women of childbearing potential should use an effective method of contraception during therapy and for at least 12 weeks after therapy has ended.

See references

Brodalumab Breastfeeding Warnings

No information is available on the clinical use of this drug during breastfeeding; because it is a large protein molecule the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant GI tract.

UK: A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. US: Benefit should outweigh risk. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: -The effects in the breastfed infant are unknown. -This drug is a monoclonal antibody and is expected to be present in the first milk and at low levels afterwards.

See references

References for pregnancy information

  1. "Product Information. Siliq (brodalumab)." Valeant Pharmaceuticals, Costa Mesa, CA.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. "Product Information. Siliq (brodalumab)." Valeant Pharmaceuticals, Costa Mesa, CA.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide